Opinion|Videos|September 4, 2024
Individualized Management of Central Precocious Puberty
Pediatric endocrinologists explore comprehensive, individualized treatment strategies for Central Precocious Puberty that extend beyond considerations of chronological and bone age.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When developing an individualized treatment strategy for CPP that goes beyond chronological age and bone age, what should pediatric endocrinologists consider?
- Can you describe the importance of data such as height velocity, bone-age-to-chronological-age ratio, and predicted adult height?
- How do you evaluate patients that are on treatment for CPP?
Advertisement
Related to this article
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.
Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.
Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.
Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.
A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.
FDA authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks glucose and ketones, for patients 2 and older with diabetes.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
3
Starting HPV vaccination earlier gives pediatricians more opportunities to protect children
4
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
5